Review



anti-cd31 antibody 77699  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc anti-cd31 antibody 77699
    (A-B) Representative images (panel A; 4× magnification) and quantification (B; based on 10× field images) of <t>CD31</t> + cells in subcutaneously established RENCA tumors subjected to daily intratumoral injection for 19 days with either C74 or equivalent amount of DMSO control. in Balb/c mice (**, p < 0.01; n = 5 mice/group; scale bar, 200 μm). C) Mass spectrometry confirmation of C74 encapsulation in lipid microbubbles. Only C74 characteristic mass peak was detected in microbubble samples. D-E) Representative cord-formation images of HmVECs for various treatment settings ( panel D ): NT: DMSO (vehicle control); C74: treatment with unencapsulated C74; MB US: empty MB with UTMD, C74 MB: C74-encapsulated MB with no UTMD; C74 MB US: C74-encapsulated MB with UTMD, and C74 US: C74-encapsulated MB with UTMD followed by immediate washout and replacement with C74-devoid culture media. The bar graph in panel E depicts the relative lengths of cords compared between the different treatment groups. **** p <0.0001 from n = 3 experiments. F-I) Ultrasound images ( panel F ) showing microbubble (MB) infiltration into tumor vasculature (white arrows), followed by UTMD and no contrast remaining in the tumor space. Images of representative subcutaneous RENCA tumors subjected to UTMD of control vs C74-encapsulated microbubbles ( panel G ) with end-point tumor burden comparison between the two treatment groups ( panel H ). Representative H&E images ( panel I; white arrows indicate functional tumor-associated blood vessels with presence of red blood cells) and the associated quantification ( panel J ) of the average number of tumor-associated blood vessels per 20X field of observation between the two treatment groups (** p < 0.01; data pooled from 8-9 mice per group; scale bar, 50 μm).
    Anti Cd31 Antibody 77699, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-cd31 antibody 77699/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    anti-cd31 antibody 77699 - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Small molecule intervention of actin-binding protein profilin1 reduces tumor angiogenesis in renal cell carcinoma"

    Article Title: Small molecule intervention of actin-binding protein profilin1 reduces tumor angiogenesis in renal cell carcinoma

    Journal: bioRxiv

    doi: 10.1101/2025.07.18.665115

    (A-B) Representative images (panel A; 4× magnification) and quantification (B; based on 10× field images) of CD31 + cells in subcutaneously established RENCA tumors subjected to daily intratumoral injection for 19 days with either C74 or equivalent amount of DMSO control. in Balb/c mice (**, p < 0.01; n = 5 mice/group; scale bar, 200 μm). C) Mass spectrometry confirmation of C74 encapsulation in lipid microbubbles. Only C74 characteristic mass peak was detected in microbubble samples. D-E) Representative cord-formation images of HmVECs for various treatment settings ( panel D ): NT: DMSO (vehicle control); C74: treatment with unencapsulated C74; MB US: empty MB with UTMD, C74 MB: C74-encapsulated MB with no UTMD; C74 MB US: C74-encapsulated MB with UTMD, and C74 US: C74-encapsulated MB with UTMD followed by immediate washout and replacement with C74-devoid culture media. The bar graph in panel E depicts the relative lengths of cords compared between the different treatment groups. **** p <0.0001 from n = 3 experiments. F-I) Ultrasound images ( panel F ) showing microbubble (MB) infiltration into tumor vasculature (white arrows), followed by UTMD and no contrast remaining in the tumor space. Images of representative subcutaneous RENCA tumors subjected to UTMD of control vs C74-encapsulated microbubbles ( panel G ) with end-point tumor burden comparison between the two treatment groups ( panel H ). Representative H&E images ( panel I; white arrows indicate functional tumor-associated blood vessels with presence of red blood cells) and the associated quantification ( panel J ) of the average number of tumor-associated blood vessels per 20X field of observation between the two treatment groups (** p < 0.01; data pooled from 8-9 mice per group; scale bar, 50 μm).
    Figure Legend Snippet: (A-B) Representative images (panel A; 4× magnification) and quantification (B; based on 10× field images) of CD31 + cells in subcutaneously established RENCA tumors subjected to daily intratumoral injection for 19 days with either C74 or equivalent amount of DMSO control. in Balb/c mice (**, p < 0.01; n = 5 mice/group; scale bar, 200 μm). C) Mass spectrometry confirmation of C74 encapsulation in lipid microbubbles. Only C74 characteristic mass peak was detected in microbubble samples. D-E) Representative cord-formation images of HmVECs for various treatment settings ( panel D ): NT: DMSO (vehicle control); C74: treatment with unencapsulated C74; MB US: empty MB with UTMD, C74 MB: C74-encapsulated MB with no UTMD; C74 MB US: C74-encapsulated MB with UTMD, and C74 US: C74-encapsulated MB with UTMD followed by immediate washout and replacement with C74-devoid culture media. The bar graph in panel E depicts the relative lengths of cords compared between the different treatment groups. **** p <0.0001 from n = 3 experiments. F-I) Ultrasound images ( panel F ) showing microbubble (MB) infiltration into tumor vasculature (white arrows), followed by UTMD and no contrast remaining in the tumor space. Images of representative subcutaneous RENCA tumors subjected to UTMD of control vs C74-encapsulated microbubbles ( panel G ) with end-point tumor burden comparison between the two treatment groups ( panel H ). Representative H&E images ( panel I; white arrows indicate functional tumor-associated blood vessels with presence of red blood cells) and the associated quantification ( panel J ) of the average number of tumor-associated blood vessels per 20X field of observation between the two treatment groups (** p < 0.01; data pooled from 8-9 mice per group; scale bar, 50 μm).

    Techniques Used: Injection, Control, Mass Spectrometry, Encapsulation, Comparison, Functional Assay

    Representative images of CD31 immunohistochemistry with hematoxylin counterstaining (panel A; 4× magnification) and quantification (panel B; based on 20X field images) of CD31+ cell infiltration in the subcutaneously implanted Matrigel plugs in Balb/C mice co-injected with a single 200 µM dosage of either C74 or 6 or DMSO control. Data are summarized from quantification of 10 bilaterally injected plugs (n=5 mice) per treatment group (**, p < 0.01; ****, p < 0.0001; scale bar, 200 μm).
    Figure Legend Snippet: Representative images of CD31 immunohistochemistry with hematoxylin counterstaining (panel A; 4× magnification) and quantification (panel B; based on 20X field images) of CD31+ cell infiltration in the subcutaneously implanted Matrigel plugs in Balb/C mice co-injected with a single 200 µM dosage of either C74 or 6 or DMSO control. Data are summarized from quantification of 10 bilaterally injected plugs (n=5 mice) per treatment group (**, p < 0.01; ****, p < 0.0001; scale bar, 200 μm).

    Techniques Used: Immunohistochemistry, Injection, Control



    Similar Products

    anti-cd31 antibody 77699  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc anti-cd31 antibody 77699
    (A-B) Representative images (panel A; 4× magnification) and quantification (B; based on 10× field images) of <t>CD31</t> + cells in subcutaneously established RENCA tumors subjected to daily intratumoral injection for 19 days with either C74 or equivalent amount of DMSO control. in Balb/c mice (**, p < 0.01; n = 5 mice/group; scale bar, 200 μm). C) Mass spectrometry confirmation of C74 encapsulation in lipid microbubbles. Only C74 characteristic mass peak was detected in microbubble samples. D-E) Representative cord-formation images of HmVECs for various treatment settings ( panel D ): NT: DMSO (vehicle control); C74: treatment with unencapsulated C74; MB US: empty MB with UTMD, C74 MB: C74-encapsulated MB with no UTMD; C74 MB US: C74-encapsulated MB with UTMD, and C74 US: C74-encapsulated MB with UTMD followed by immediate washout and replacement with C74-devoid culture media. The bar graph in panel E depicts the relative lengths of cords compared between the different treatment groups. **** p <0.0001 from n = 3 experiments. F-I) Ultrasound images ( panel F ) showing microbubble (MB) infiltration into tumor vasculature (white arrows), followed by UTMD and no contrast remaining in the tumor space. Images of representative subcutaneous RENCA tumors subjected to UTMD of control vs C74-encapsulated microbubbles ( panel G ) with end-point tumor burden comparison between the two treatment groups ( panel H ). Representative H&E images ( panel I; white arrows indicate functional tumor-associated blood vessels with presence of red blood cells) and the associated quantification ( panel J ) of the average number of tumor-associated blood vessels per 20X field of observation between the two treatment groups (** p < 0.01; data pooled from 8-9 mice per group; scale bar, 50 μm).
    Anti Cd31 Antibody 77699, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-cd31 antibody 77699/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    anti-cd31 antibody 77699 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    cd31  (Cell Signaling Technology Inc)
    97
    Cell Signaling Technology Inc cd31
    (A-B) Representative images (panel A; 4× magnification) and quantification (B; based on 10× field images) of <t>CD31</t> + cells in subcutaneously established RENCA tumors subjected to daily intratumoral injection for 19 days with either C74 or equivalent amount of DMSO control. in Balb/c mice (**, p < 0.01; n = 5 mice/group; scale bar, 200 μm). C) Mass spectrometry confirmation of C74 encapsulation in lipid microbubbles. Only C74 characteristic mass peak was detected in microbubble samples. D-E) Representative cord-formation images of HmVECs for various treatment settings ( panel D ): NT: DMSO (vehicle control); C74: treatment with unencapsulated C74; MB US: empty MB with UTMD, C74 MB: C74-encapsulated MB with no UTMD; C74 MB US: C74-encapsulated MB with UTMD, and C74 US: C74-encapsulated MB with UTMD followed by immediate washout and replacement with C74-devoid culture media. The bar graph in panel E depicts the relative lengths of cords compared between the different treatment groups. **** p <0.0001 from n = 3 experiments. F-I) Ultrasound images ( panel F ) showing microbubble (MB) infiltration into tumor vasculature (white arrows), followed by UTMD and no contrast remaining in the tumor space. Images of representative subcutaneous RENCA tumors subjected to UTMD of control vs C74-encapsulated microbubbles ( panel G ) with end-point tumor burden comparison between the two treatment groups ( panel H ). Representative H&E images ( panel I; white arrows indicate functional tumor-associated blood vessels with presence of red blood cells) and the associated quantification ( panel J ) of the average number of tumor-associated blood vessels per 20X field of observation between the two treatment groups (** p < 0.01; data pooled from 8-9 mice per group; scale bar, 50 μm).
    Cd31, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd31/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    cd31 - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier
    species reactivity with mouse  (Cell Signaling Technology Inc)
    97
    Cell Signaling Technology Inc species reactivity with mouse
    (A-B) Representative images (panel A; 4× magnification) and quantification (B; based on 10× field images) of <t>CD31</t> + cells in subcutaneously established RENCA tumors subjected to daily intratumoral injection for 19 days with either C74 or equivalent amount of DMSO control. in Balb/c mice (**, p < 0.01; n = 5 mice/group; scale bar, 200 μm). C) Mass spectrometry confirmation of C74 encapsulation in lipid microbubbles. Only C74 characteristic mass peak was detected in microbubble samples. D-E) Representative cord-formation images of HmVECs for various treatment settings ( panel D ): NT: DMSO (vehicle control); C74: treatment with unencapsulated C74; MB US: empty MB with UTMD, C74 MB: C74-encapsulated MB with no UTMD; C74 MB US: C74-encapsulated MB with UTMD, and C74 US: C74-encapsulated MB with UTMD followed by immediate washout and replacement with C74-devoid culture media. The bar graph in panel E depicts the relative lengths of cords compared between the different treatment groups. **** p <0.0001 from n = 3 experiments. F-I) Ultrasound images ( panel F ) showing microbubble (MB) infiltration into tumor vasculature (white arrows), followed by UTMD and no contrast remaining in the tumor space. Images of representative subcutaneous RENCA tumors subjected to UTMD of control vs C74-encapsulated microbubbles ( panel G ) with end-point tumor burden comparison between the two treatment groups ( panel H ). Representative H&E images ( panel I; white arrows indicate functional tumor-associated blood vessels with presence of red blood cells) and the associated quantification ( panel J ) of the average number of tumor-associated blood vessels per 20X field of observation between the two treatment groups (** p < 0.01; data pooled from 8-9 mice per group; scale bar, 50 μm).
    Species Reactivity With Mouse, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/species reactivity with mouse/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    species reactivity with mouse - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier
    anti-cd31 cell signaling 77699  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc anti-cd31 cell signaling 77699
    (A-B) Representative images (panel A; 4× magnification) and quantification (B; based on 10× field images) of <t>CD31</t> + cells in subcutaneously established RENCA tumors subjected to daily intratumoral injection for 19 days with either C74 or equivalent amount of DMSO control. in Balb/c mice (**, p < 0.01; n = 5 mice/group; scale bar, 200 μm). C) Mass spectrometry confirmation of C74 encapsulation in lipid microbubbles. Only C74 characteristic mass peak was detected in microbubble samples. D-E) Representative cord-formation images of HmVECs for various treatment settings ( panel D ): NT: DMSO (vehicle control); C74: treatment with unencapsulated C74; MB US: empty MB with UTMD, C74 MB: C74-encapsulated MB with no UTMD; C74 MB US: C74-encapsulated MB with UTMD, and C74 US: C74-encapsulated MB with UTMD followed by immediate washout and replacement with C74-devoid culture media. The bar graph in panel E depicts the relative lengths of cords compared between the different treatment groups. **** p <0.0001 from n = 3 experiments. F-I) Ultrasound images ( panel F ) showing microbubble (MB) infiltration into tumor vasculature (white arrows), followed by UTMD and no contrast remaining in the tumor space. Images of representative subcutaneous RENCA tumors subjected to UTMD of control vs C74-encapsulated microbubbles ( panel G ) with end-point tumor burden comparison between the two treatment groups ( panel H ). Representative H&E images ( panel I; white arrows indicate functional tumor-associated blood vessels with presence of red blood cells) and the associated quantification ( panel J ) of the average number of tumor-associated blood vessels per 20X field of observation between the two treatment groups (** p < 0.01; data pooled from 8-9 mice per group; scale bar, 50 μm).
    Anti Cd31 Cell Signaling 77699, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-cd31 cell signaling 77699/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    anti-cd31 cell signaling 77699 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    rabbit monoclonal anti-taut antibody 77699  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc rabbit monoclonal anti-taut antibody 77699
    (A-B) Representative images (panel A; 4× magnification) and quantification (B; based on 10× field images) of <t>CD31</t> + cells in subcutaneously established RENCA tumors subjected to daily intratumoral injection for 19 days with either C74 or equivalent amount of DMSO control. in Balb/c mice (**, p < 0.01; n = 5 mice/group; scale bar, 200 μm). C) Mass spectrometry confirmation of C74 encapsulation in lipid microbubbles. Only C74 characteristic mass peak was detected in microbubble samples. D-E) Representative cord-formation images of HmVECs for various treatment settings ( panel D ): NT: DMSO (vehicle control); C74: treatment with unencapsulated C74; MB US: empty MB with UTMD, C74 MB: C74-encapsulated MB with no UTMD; C74 MB US: C74-encapsulated MB with UTMD, and C74 US: C74-encapsulated MB with UTMD followed by immediate washout and replacement with C74-devoid culture media. The bar graph in panel E depicts the relative lengths of cords compared between the different treatment groups. **** p <0.0001 from n = 3 experiments. F-I) Ultrasound images ( panel F ) showing microbubble (MB) infiltration into tumor vasculature (white arrows), followed by UTMD and no contrast remaining in the tumor space. Images of representative subcutaneous RENCA tumors subjected to UTMD of control vs C74-encapsulated microbubbles ( panel G ) with end-point tumor burden comparison between the two treatment groups ( panel H ). Representative H&E images ( panel I; white arrows indicate functional tumor-associated blood vessels with presence of red blood cells) and the associated quantification ( panel J ) of the average number of tumor-associated blood vessels per 20X field of observation between the two treatment groups (** p < 0.01; data pooled from 8-9 mice per group; scale bar, 50 μm).
    Rabbit Monoclonal Anti Taut Antibody 77699, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit monoclonal anti-taut antibody 77699/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    rabbit monoclonal anti-taut antibody 77699 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    cd31 antibody  (Cell Signaling Technology Inc)
    97
    Cell Signaling Technology Inc cd31 antibody
    (A-B) Representative images (panel A; 4× magnification) and quantification (B; based on 10× field images) of <t>CD31</t> + cells in subcutaneously established RENCA tumors subjected to daily intratumoral injection for 19 days with either C74 or equivalent amount of DMSO control. in Balb/c mice (**, p < 0.01; n = 5 mice/group; scale bar, 200 μm). C) Mass spectrometry confirmation of C74 encapsulation in lipid microbubbles. Only C74 characteristic mass peak was detected in microbubble samples. D-E) Representative cord-formation images of HmVECs for various treatment settings ( panel D ): NT: DMSO (vehicle control); C74: treatment with unencapsulated C74; MB US: empty MB with UTMD, C74 MB: C74-encapsulated MB with no UTMD; C74 MB US: C74-encapsulated MB with UTMD, and C74 US: C74-encapsulated MB with UTMD followed by immediate washout and replacement with C74-devoid culture media. The bar graph in panel E depicts the relative lengths of cords compared between the different treatment groups. **** p <0.0001 from n = 3 experiments. F-I) Ultrasound images ( panel F ) showing microbubble (MB) infiltration into tumor vasculature (white arrows), followed by UTMD and no contrast remaining in the tumor space. Images of representative subcutaneous RENCA tumors subjected to UTMD of control vs C74-encapsulated microbubbles ( panel G ) with end-point tumor burden comparison between the two treatment groups ( panel H ). Representative H&E images ( panel I; white arrows indicate functional tumor-associated blood vessels with presence of red blood cells) and the associated quantification ( panel J ) of the average number of tumor-associated blood vessels per 20X field of observation between the two treatment groups (** p < 0.01; data pooled from 8-9 mice per group; scale bar, 50 μm).
    Cd31 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd31 antibody/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    cd31 antibody - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    (A-B) Representative images (panel A; 4× magnification) and quantification (B; based on 10× field images) of CD31 + cells in subcutaneously established RENCA tumors subjected to daily intratumoral injection for 19 days with either C74 or equivalent amount of DMSO control. in Balb/c mice (**, p < 0.01; n = 5 mice/group; scale bar, 200 μm). C) Mass spectrometry confirmation of C74 encapsulation in lipid microbubbles. Only C74 characteristic mass peak was detected in microbubble samples. D-E) Representative cord-formation images of HmVECs for various treatment settings ( panel D ): NT: DMSO (vehicle control); C74: treatment with unencapsulated C74; MB US: empty MB with UTMD, C74 MB: C74-encapsulated MB with no UTMD; C74 MB US: C74-encapsulated MB with UTMD, and C74 US: C74-encapsulated MB with UTMD followed by immediate washout and replacement with C74-devoid culture media. The bar graph in panel E depicts the relative lengths of cords compared between the different treatment groups. **** p <0.0001 from n = 3 experiments. F-I) Ultrasound images ( panel F ) showing microbubble (MB) infiltration into tumor vasculature (white arrows), followed by UTMD and no contrast remaining in the tumor space. Images of representative subcutaneous RENCA tumors subjected to UTMD of control vs C74-encapsulated microbubbles ( panel G ) with end-point tumor burden comparison between the two treatment groups ( panel H ). Representative H&E images ( panel I; white arrows indicate functional tumor-associated blood vessels with presence of red blood cells) and the associated quantification ( panel J ) of the average number of tumor-associated blood vessels per 20X field of observation between the two treatment groups (** p < 0.01; data pooled from 8-9 mice per group; scale bar, 50 μm).

    Journal: bioRxiv

    Article Title: Small molecule intervention of actin-binding protein profilin1 reduces tumor angiogenesis in renal cell carcinoma

    doi: 10.1101/2025.07.18.665115

    Figure Lengend Snippet: (A-B) Representative images (panel A; 4× magnification) and quantification (B; based on 10× field images) of CD31 + cells in subcutaneously established RENCA tumors subjected to daily intratumoral injection for 19 days with either C74 or equivalent amount of DMSO control. in Balb/c mice (**, p < 0.01; n = 5 mice/group; scale bar, 200 μm). C) Mass spectrometry confirmation of C74 encapsulation in lipid microbubbles. Only C74 characteristic mass peak was detected in microbubble samples. D-E) Representative cord-formation images of HmVECs for various treatment settings ( panel D ): NT: DMSO (vehicle control); C74: treatment with unencapsulated C74; MB US: empty MB with UTMD, C74 MB: C74-encapsulated MB with no UTMD; C74 MB US: C74-encapsulated MB with UTMD, and C74 US: C74-encapsulated MB with UTMD followed by immediate washout and replacement with C74-devoid culture media. The bar graph in panel E depicts the relative lengths of cords compared between the different treatment groups. **** p <0.0001 from n = 3 experiments. F-I) Ultrasound images ( panel F ) showing microbubble (MB) infiltration into tumor vasculature (white arrows), followed by UTMD and no contrast remaining in the tumor space. Images of representative subcutaneous RENCA tumors subjected to UTMD of control vs C74-encapsulated microbubbles ( panel G ) with end-point tumor burden comparison between the two treatment groups ( panel H ). Representative H&E images ( panel I; white arrows indicate functional tumor-associated blood vessels with presence of red blood cells) and the associated quantification ( panel J ) of the average number of tumor-associated blood vessels per 20X field of observation between the two treatment groups (** p < 0.01; data pooled from 8-9 mice per group; scale bar, 50 μm).

    Article Snippet: Tissue sections were deparaffinized and rehydrated before blocking and incubating overnight with an anti-CD31 antibody (77699, Cell Signaling Technology, 1:100).

    Techniques: Injection, Control, Mass Spectrometry, Encapsulation, Comparison, Functional Assay

    Representative images of CD31 immunohistochemistry with hematoxylin counterstaining (panel A; 4× magnification) and quantification (panel B; based on 20X field images) of CD31+ cell infiltration in the subcutaneously implanted Matrigel plugs in Balb/C mice co-injected with a single 200 µM dosage of either C74 or 6 or DMSO control. Data are summarized from quantification of 10 bilaterally injected plugs (n=5 mice) per treatment group (**, p < 0.01; ****, p < 0.0001; scale bar, 200 μm).

    Journal: bioRxiv

    Article Title: Small molecule intervention of actin-binding protein profilin1 reduces tumor angiogenesis in renal cell carcinoma

    doi: 10.1101/2025.07.18.665115

    Figure Lengend Snippet: Representative images of CD31 immunohistochemistry with hematoxylin counterstaining (panel A; 4× magnification) and quantification (panel B; based on 20X field images) of CD31+ cell infiltration in the subcutaneously implanted Matrigel plugs in Balb/C mice co-injected with a single 200 µM dosage of either C74 or 6 or DMSO control. Data are summarized from quantification of 10 bilaterally injected plugs (n=5 mice) per treatment group (**, p < 0.01; ****, p < 0.0001; scale bar, 200 μm).

    Article Snippet: Tissue sections were deparaffinized and rehydrated before blocking and incubating overnight with an anti-CD31 antibody (77699, Cell Signaling Technology, 1:100).

    Techniques: Immunohistochemistry, Injection, Control